Monday, August 16, 2021 4:11:26 PM
NS
Pfizer is making money, no doubt. The specifics of the agreement may be confidential but this is a mutually beneficial agreement.
HLS was at a crossroads. They have less than 25 reps for the whole country. No point adding during Covid because they couldn’t get in the doors of the cardiologists office. They focused on larger speaker events online with big names and getting on the treatment guidelines. Done
Now that things are opening they had to decide to hire a lot of reps and train them or “merge” with an existing sales force to move much faster and use people with existing relationships in the cardiovascular community. Pfizer was a perfect fit. They will get a percentage sales or milestone payments or whatever but this is the Pfizer sales force trying to create revenue for Pfizer as well.
This was also an internal/national decision by HLS and Pfizer Canada on how both could make money. I doubt they needed Amarin’s approval - they clearly own the rights for V in Canada and can do what they want OTHER THAN UNDERCUT ON PRICE which could cause Amarin problems negotiating prices in EU and ROW.
Pfizer is interested in V - no question. They may be putting a toe in the water here but it’s not a test to buy US. Completely different market - although very similar to EU.
The US is one of the only for profit healthcare countries in the developed world and therefore it is a different game there compared to almost everywhere else.
I’m still surprised the stock went down on such news but after all it is Amarin.
Pfizer is making money, no doubt. The specifics of the agreement may be confidential but this is a mutually beneficial agreement.
HLS was at a crossroads. They have less than 25 reps for the whole country. No point adding during Covid because they couldn’t get in the doors of the cardiologists office. They focused on larger speaker events online with big names and getting on the treatment guidelines. Done
Now that things are opening they had to decide to hire a lot of reps and train them or “merge” with an existing sales force to move much faster and use people with existing relationships in the cardiovascular community. Pfizer was a perfect fit. They will get a percentage sales or milestone payments or whatever but this is the Pfizer sales force trying to create revenue for Pfizer as well.
This was also an internal/national decision by HLS and Pfizer Canada on how both could make money. I doubt they needed Amarin’s approval - they clearly own the rights for V in Canada and can do what they want OTHER THAN UNDERCUT ON PRICE which could cause Amarin problems negotiating prices in EU and ROW.
Pfizer is interested in V - no question. They may be putting a toe in the water here but it’s not a test to buy US. Completely different market - although very similar to EU.
The US is one of the only for profit healthcare countries in the developed world and therefore it is a different game there compared to almost everywhere else.
I’m still surprised the stock went down on such news but after all it is Amarin.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
